699 filings
Page 6 of 35
8-K
8uxu0ci3t6zx227
15 Mar 16
Repros Announces Initiation of Formal Approval Process by the European Medicines Agency
12:00am
8-K
krmok642ndm1m3z0
14 Mar 16
Repros Therapeutics Inc.® Reports Fourth Quarter and Year End 2015 Financial Results
12:00am
8-K
un5ll5tv84
16 Feb 16
Repros Completes Randomization of Enclomiphene Phase 2 Proof of Concept Study in Obese Secondary Hypogonadal Men
12:00am
8-K
fneij3dnh7 o14f3nnus
8 Feb 16
Repros Holds Meeting With FDA to Discuss Complete Response Letter for Enclomiphene in the Treatment of Secondary Hypogonadism
12:00am
25-NSE
hvqi0ehjyu9d3doqpe
3 Feb 16
Exchange delisting
12:00am
8-K
bz0hgneg1
11 Jan 16
Repros Announces Court of Appeals’ Affirmation of Summary Judgment in Favor of the Company
12:00am
8-K
qgvo50elqqz
6 Jan 16
Departure of Directors or Certain Officers
12:00am
8-K
fjamd1 yv5
4 Jan 16
Repros Updates Enclomiphene Program
12:00am
8-K
rupvadz9jk77zjt5r0a
21 Dec 15
Repros Updates Proellex® Program
12:00am
8-K
cz38d45k8f06 mb3bz19
1 Dec 15
Regulation FD Disclosure
12:00am
8-K
x5ur0zjdhk 2t
17 Nov 15
Enclomiphene ( EnCyzix ™) A Mechanistically Consistent Approach to the Treatment of Secondary Hypogonadism
12:00am
8-K
sl25wbg nmdked49wp
16 Nov 15
Departure of Directors or Certain Officers
12:00am
8-K
7usogh k5
12 Nov 15
Regulation FD Disclosure
12:00am
8-K
dk76lpmlcc4qkeco2geb
9 Nov 15
Results of Operations and Financial Condition
12:00am
8-K
46sauafwcbia4c3 hv
29 Oct 15
Regulation FD Disclosure
12:00am
8-K
cirl807369wz5w
29 Sep 15
Enclomiphene ( EnCyzix ™) A Mechanistically Consistent Approach to the Treatment of Secondary Hypogonadism
12:00am
8-K
fwhewmjoyd
10 Aug 15
Results of Operations and Financial Condition
12:00am